Screener
Avalo Therapeutics AVTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Investing activities | ||
| Purchases of investments | (353,801) | (70,860) |
| Sales and maturities of investments | 49,381 | — |
| Net cash used in investing activities | (304,420) | (70,860) |
| Financing activities | ||
| Proceeds from sale of common stock and pre-funded warrants in an underwritten public offering, gross | 431,315 | — |
| Transaction costs paid pursuant to sale of common stock and pre-funded warrants in an underwritten public offering | (26,403) | — |
| Proceeds from exercise of stock options | 7,409 | — |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's investing cash flow?
- Avalo Therapeutics (AVTX) reported investing cash flow of -$329.93M in Q2 2026.
- How has Avalo Therapeutics's investing cash flow changed year-over-year?
- Avalo Therapeutics's investing cash flow decreased by 365.6% year-over-year, from -$70.86M to -$329.93M.
- What is the long-term trend for Avalo Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Avalo Therapeutics's investing cash flow has grown at a 2628.4% compound annual growth rate (CAGR), from -$113K to -$84.12M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Avalo Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude